Real-world observational data in costeffectiveness analyses: Herceptin as a case study

Size: px
Start display at page:

Download "Real-world observational data in costeffectiveness analyses: Herceptin as a case study"

Transcription

1 Real-world observational data in costeffectiveness analyses: Herceptin as a case study DR BONNY PARKINSON, PROFESSOR ROSALIE VINEY, ASSOCIATE PROFESSOR STEPHEN GOODALL AND PROFESSOR MARION HAAS ISPOR AUSTRALIA CONTEMPORARY ECONOMIC MODELLING WORKSHOP - 17 MARCH 2016

2 Background and motivation 2/15 A key challenge for decision makers is whether: Predicted costeffectiveness when the decision is made (based on clinical trials)? Costeffectiveness in real-world clinical practice CENTRE FOR THE HEALTH ECONOMY 2

3 Background and motivation 3/15 Randomised controlled clinical trials (RCTs) are the key source of efficacy Considered the gold standard approach But initial RCTs conducted for regulatory purposes: Are often conducted in highly selected and homogenous populations who receive protocol driven care. Often do not collect all evidence required due to ethical, practical or financial reasons Therefore the results of RCTs need to be translated into a form suitable for decision making: E.g. extrapolated beyond the trial or efficacy transformed into patient-relevant health outcomes Requires judgements about: Source of parameters Methods of analysis/synthesis Introduces uncertainty CENTRE FOR THE HEALTH ECONOMY 3

4 Background and motivation 4/15 interest in Coverage with Evidence Development (CED): Population-level payment or reimbursement linked to prospective data collection. Proposed that observational data collected post-reimbursement can be used to confirm whether: Predicted costeffectiveness when the decision is made (based on clinical trials)? Costeffectiveness in real-world clinical practice CENTRE FOR THE HEALTH ECONOMY 4

5 Aims 1) To what extent and why might the cost-effectiveness of a treatment differ in clinical practice from that predicted using clinical trial data? 2) What is the value of collecting real-world observational data? 3) When should a Coverage with Evidence Development (CED) arrangement be implemented instead of other risk-sharing arrangements? CENTRE FOR THE HEALTH ECONOMY 5

6 Case-study: trastuzumab (Herceptin) 6/15 HER2+ breast cancer HER2+ prognosis (15% patients are HER2+) time to progression and overall survival In 2000 and 2001 PBAC rejected 3 submissions trastuzumab for HER2+ metastatic breast cancer (MBC) No evidence of overall survival Expensive: $52,000 for 12 months Unacceptably high ICER Government established the Herceptin Program in December 2001 Rich observational dataset: Captured treatment of almost all patients CENTRE FOR THE HEALTH ECONOMY 6

7 Methods THREE STAGES 1) An economic model of trastuzumab for the treatment of HER2+ MBC was developed using trial evidence and analysed using value of information methods. 2) Observational data from the Herceptin Program were analysed to inform modifications to model parameters. 3) The model was adjusted to estimate the real-world costeffectiveness of trastuzumab for the treatment of HER2+ MBC CENTRE FOR THE HEALTH ECONOMY 7

8 Stage 1 AN ECONOMIC MODEL WAS DEVELOPED USING TRIAL EVIDENCE AND ANALYSED USING VALUE OF INFORMATION METHODS

9 Methods MODEL STRUCTURE 9/15 Reflected first-line treatment of HER2+ MBC with trastuzumab Similar to that which would have been considered by the PBAC in 2001 Built in TreeAge 2013 CENTRE FOR THE HEALTH ECONOMY HER2 testing decision tree Markov model 9

10 Methods MODEL STRUCTURE TWO SETS OF INPUTS Best available in 2001 and best available in Efficacy based on trial H0648g Trastuzumab + paclitaxel (n=92) vs paclitaxel (n=96) Only trial available in 2001 Clinicians may not adhere to guidelines (i.e. imperfect implementation of PBS listing) conducted sensitivity analysis of trastuzumab + other chemotherapies using RCTs that became available after 2001 CENTRE FOR THE HEALTH ECONOMY 10

11 Methods MODEL STRUCTURE TESTING Immunohistochemistry (IHC) and in situ hybridisaiton (ISH) Tests are not perfect Test +ve (including false +ve patients) trastuzumab + paclitaxel Test ve (including false -ve patients) paclitaxel EFFICACY FOLLOWING TESTING Assumed that the health outcomes following treatment with paclitaxel is independent of true HER2 status Post-hoc analysis of trial H0648g Assumed that the efficacy of trastuzumab plus paclitaxel applies regardless of the patient s true HER2 status As trial H0648g analysed on an intent to treat (ITT) basis The health outcome impact of discontinuations, dose reductions, deaths due to AEs and any second-line treatments were not explicitly modelled As trial H0648g analysed on ITT basis CENTRE FOR THE HEALTH ECONOMY 11

12 Methods INPUTS Best available data in 2001 Best available data in 2013 Test accuracy Efficacy Incidence of grade 3 adverse events (n=40) and discontinuations Published literature depending on availability Trial H0648g, Kaplan-Meier estimates were digitised using Engauge and parametric functions were fitted using STATA. When not available, based on medians and assumed a constant hazard rate of progression Trial H0648g Utilities and disutilities Hauser (2001) + published literature depending on availability Peasgood (2010) + published literature depending on availability Resource use Cost of trastuzumab HER2 testing Chemotherapy and pre-medications, chemotherapy administration Pre-progression: specialist visits, imaging and pathology Post-progression: capecitabine + as per pre-progression Palliative care and adverse events (2013 model only) Assumed = PBS listed price of trastuzumab for the treatment of early breast cancer Unit costs Reported in 2001 A$ Reported in A$ Time horizon Cycle length Outcomes Perspective Discount rate OFFICE I FACULTY I DEPARTMENT 10 years 1 week Life years gained and Quality Adjusted Life Years (QALYs) Healthcare system 5%pa for costs and outcomes 12

13 Methods SENSITIVITY ANALYSES UNIVARIATE SENSITIVITY ANALYSIS Upper and lower 95% confidence intervals SCENARIO ANALYSES Imperfect implementation of listing: use of other concomitant chemotherapies (efficacy based on RCTs that became available after 2001) trastuzumab post-progression THRESHOLD ANALYSIS ON PRICE AND RISK-SHARE ARRANGEMENTS ICER = $60,000/QALY gained or $80,000/QALY gained PROBABILISTIC SENSITIVITY ANALYSIS Uninformative priors where evidence is limited CENTRE FOR THE HEALTH ECONOMY 13

14 Methods THE VALUE OF COLLECTING OBSERVATIONAL DATA It was assumed that the manufacturer suggested that a CED arrangement be implemented with interim funding subject to: collecting observational data linked to PBS and MBS data All analyses based on 2001 model. BEST-CASE SCENARIO ANALYSIS Each parameter value was adjusted to equal the upper or lower 95% CI, depending on the results of the univariate sensitivity analysis. VALUE OF INFORMATION ANALYSIS Expected Value of Perfect Parameter Information (EVPPI)* estimated using Monte Carlo methods (i.e. simulation) It was assumed that: treatment was restricted to concomitant treatment with paclitaxel and not continued post-progression the maximum life-time of trastuzumab was 13 years ( ) 464 patients receive trastuzumab per year. Expected * difference in value the expected of sample net benefit information with perfect information (EVSI) about not a sub-set conducted of parameters because compared observational to the expected net benefit data with captures CENTRE FOR THE HEALTH ECONOMY the 14 treatment current information of almost set (or the all opportunity patients cost of making the wrong decision).

15 Results BASE CASE 15/47 Treatment arm Cost ($) Incremental cost ($) LY Life years LYG ICER ($/LYG) QALYs QALYs QALYs gained ICER ($/QALY gained) Best-available data in 2001 Paclitaxel only available 16, Trastuzumab available 44,803 28, , ,910 Best-available data in 2013 Paclitaxel only available 27, Trastuzumab available 40,576 13, , ,245 ICER > range considered acceptable BUT the ICER is likely to be over-estimated due to cross-over. Decrease in QALYs gained due to: - different testing parameters - lower utility values - inclusion of additional disutilities associated with AEs. Decrease in incremental costs due to: - availability of the smaller vial - ability to administer trastuzumab three-weekly - a decrease in the PBS cost of paclitaxel due to the loss of patent protection in CENTRE FOR THE HEALTH ECONOMY 15

16 Results BASE CASE 16/47 Most sensitive to: Odds ratio and probability of an adverse event Hazard rate ratio (HRR) and duration of time to progression (TTP) CENTRE FOR THE HEALTH ECONOMY OR of AEs (95%CIs) Probability of AEs (95%CIs) Duration of TTP with chemotherapy (95%CIs) HRR of TTP (95%CIs) OR of response with trastuzumab (95%CIs) Probability of response with chemotherapy (95%CIs) HRR of OS (95%CIs) Duration of OS with chemotherapy (95%CIs) Disutility AEs (95%CIs) Utility response (95%CIs) Utility stable disease (95%CIs) Utility progressive disease (95%CIs) OR of discontinuation (95%CIs) Probability of discontinuation (95%CIs) Dose reduction (95%CIs) Frequency of cardiac testing, ECHO/MUGA and ECG (95%CIs) Frequency of CT scans (95% CIs) Probability outpatient (95%CIs) Trastuzumab cost -10% (0% in base case) Probability public given inpatient (95%CIs) Duration of hospitalisation for AEs (95%CIs) Duration of treatment with chemotherapy (upper 95%CI) Cost of palliative care (95%CIs) Cost of AE treatment in hospital (95%CIs) Cost of treatment administration in hospital (95%CIs) Probability trastuzumab weekly (95%CIs) Proportion using CVAD (95%CIs) Frequency of specialist visits(95%cis) Cost of treatment with chemotherapy post progression (95%CIs) Duration of treatment with chemotherapy post progression (95%CIs) Proportion using ECHO vs MUGA (95%CIs) Frequency of pathology tests (95%CIs) Discount rate = 3% and 7% (5% in base case) Time horizon +/-10% (520 in base case) Probability test results in true positive (95%CIs) Probability test results in true negative (95%CIs) HER2+ prevalence (95%CIs) Dominated $0 $50 $100 $150 $200 $ ICER ($/QALY gained) Thousands

17 Results BASE CASE 17/47 Paclitaxel most cost-effective concomitant chemotherapy Trastuzumab continued post progression ICER Assumes not treatment benefit Base case model, no treatment post-progression Model 2, no treatment post-progression Model 3, no treatment post-progression Model 4, no treatment post-progression Model 5, no treatment post-progression Model 6, no treatment post-progression Base case model, with treatment post-progression Model 2, with treatment post-progression Model 3, with treatment post-progression Model 4, with treatment post-progression Model 5, with treatment post-progression Model 6, with treatment post-progression $0 $100 $200 $300 $400 ICER ($/QALY gained) Thousands CENTRE FOR THE HEALTH ECONOMY 17

18 Results PROBABILISTIC SENSITIVITY ANALYSIS 18/47 Very low probability of being cost-effective Incremental costs ($) 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10, QALYs gained Probability Cost-effective 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 0 50, , , , , ,000 Willingness to pay ($/QALY gained) Chemotherapy only available, no price discount or dose cap With 80% price discount With 24 week dose cap With $8,000 per patient fixed price Trastuzumab available, no price discount or dose cap With 80% price discount With 24 week dose cap With $8,000 per patient fixed price CENTRE FOR THE HEALTH ECONOMY 18

19 Results THRESHOLD ANALYSIS 19/47 For the ICER = $60,000/QALY gained 96% price discount needed For the ICER = $80,000/QALY gained 80% price discount needed Alternatively a dose cap of 24 weeks or a fixed cost of $8,000 per patient would be needed for the ICER =$80,000/QALY gained. Unrealistic in the long-term, but may be reasonable in the short-term while research is conducted. CENTRE FOR THE HEALTH ECONOMY 19

20 Results THE VALUE OF COLLECTING OBSERVATIONAL DATA 20/47 BEST CASE SCENARIO ANALYSIS Best case without price discount = $113,067/QALY gained Best case with price discount = below $80,000/QALY gained VALUE OF INFORMATION Population EVPPI without price discount = $0 Population EVPPI with price discount > $0 Population EVPPI ($) Millions $7.0 $6.0 $5.0 $4.0 $3.0 $2.0 $1.0 No price discount, observational data + MBS data + PBS data (+/- admitted patient data) 81% price discount, observational data + MBS data + PBS data 81% price discount,observational data + MBS data + PBS data + admitted patient data 24 week dose cap, observational data + MBS data + PBS data CENTRE FOR THE HEALTH ECONOMY $ Time to collect data (years) $8,000 per patient fixed price, observational data + MBS data + PBS data 20

21 Stage 2 OBSERVATIONAL DATA WERE ANALYSED TO INFORM MODIFICATIONS TO MODEL PARAMETERS

22 Methods SAMPLE Patients who received treatment between December 2001 and March Analysis included 3617 patients Linked to PBS and MBS data ANALYSIS Resource use: Trastuzumab: dosage regimen and treatment duration Chemotherapies administered pre- and post-progression: type and treatment duration Medical services: baseline and time between services Health outcomes: Overall survival based on date of death Progression free survival based on a proxy (Joshi et al 2011) Date of progression = date of prescription of a new chemotherapy not previously administered which occurs >42 days after the start of treatment with trastuzumab OR end-date of treatment with trastuzumab if monotherapy. Estimated in STATA using Kaplan-Meier methods to account for censoring CENTRE FOR THE HEALTH ECONOMY 22

23 Results PROGNOSIS Older patients and more prior chemotherapies in clinical practice vs trials Likely poorer prognosis TESTING ISH testing in clinical practice vs trials Due to PBS restrictions on other chemotherapies Percent Percent Age of patients at enrolment on Herceptin Program Years Test used to determine HER2 status Start year of treatment IHC3+ FISH+ IHC2+ and FISH+ CENTRE FOR THE HEALTH ECONOMY 23

24 Results TRASTUZUMAB REGIMEN Three weekly dosing regimen Less resources required and more convenient for patients MEDICAL SERVICE USE VS GUIDELINES patients treated in outpatient setting and public inpatients central venous access device (CVAD) use frequent specialist visits and pathology tests frequent: CT scans, BMD scans, ECGs and ECHO/MUGA scans probability that cardiac function tested using ECHO vs MUGA scans Percent Likely treatment regimen based on weight at enrolment and mean quantity requested Start year of treatment Weekly Three weekly CENTRE FOR THE HEALTH ECONOMY 24

25 Results 25/15 INITIAL TREATMENT Broader range of concomitant chemotherapies than in guidelines (taxanes or monotherapy) or where RCT evidence is available. POST PROGRESSION TREATMENT Almost half received trastuzumab Capecitabine and lapatinib CENTRE FOR THE HEALTH ECONOMY Proportion of patients Selected chemotherapies used after disease progression Year that treatment ceased Capecitabine Docetaxel Aromatase Gemcitabine Carboplatin Paclitaxel Vinorelbine Lapatinib Doxorubicin Trastuzumab via Herceptin Program 25 25

26 Results 26/15 TTP/PFS, median weeks (95%CI) Overall survival, median weeks (95%CI) Herceptin Program Clinical trials Herceptin Program data (PFS) (TTP) data Clinical trials All patients 36.3 (34.1, 38.9) (123.6, 136.4) - Any initial concomitant 50.9 (48.3, 53.3) (142.6, 163.4) - chemotherapy Monotherapy 16.0 (14.4, 17.9) (86.4, 102.9) - By initial concomitant chemotherapies (pre-progression) Docetaxel M (40.0, 58.7) (118.7, 182.6) 50.4 (45.4, 54.1) (130.1, 154.3) TRAVIOTA** (NR) NR HERNATA 53.9 (NR) (NR) Paclitaxel H0648g 30.0 (23.0, 43.0) 96.1 (73.5, 133.5) 51.0 (48.0, 57.0) (125.9, 164.7) Gasparini (NR) NR (2007) Anthracycline 27.9 (14.0, 43.7) 33.9 (30.4, 39.1) (137.1, NA) (100.0, 143.5) Aromatase inhibitor 68.4 (63.6, 76.0) 20.9 (16.1, 33.5) (187.4, 244.1) (99.1, 184.4) Vinorelbine TRAVIOTA 39.0 (29.9, 48.1) 37.0 (NR) (72.4, 117.1) NR HERNATA 66.5 (NR) (NR) Other chemotherapy 38.4 (27.0, 49.1) (129.3, 237.3) - CENTRE FOR THE HEALTH ECONOMY Significantly progression free survival (PFS) if monotherapy. Poorer prognosis patients if administered paclitaxel if administered docetaxel or an anthracycline if administered vinorelbine Results with aromatase inhibitors should be considered with caution. Significantly overall survival if monotherapy. Poorer prognosis patients overall survival with chemotherapies Unless administered vinorelbine Poorer prognosis patients 26

27 Stage 3 THE MODEL WAS ADJUSTED TO ESTIMATE THE REAL-WORLD COST-EFFECTIVENESS OF TRASTUZUMAB.

28 Methods 28/15 Typical approach: estimate the average costs and health outcomes for patients receiving a particular treatment or a comparator in an observational dataset. Selection bias issues Often don t have a control group Aimed to adjust health outcomes to reflect real-world clinical practice while leaving relative efficacy unchanged. 28

29 Methods 29/47 Based on the statistical analysis of the Herceptin Program data: Step 1: Modify the resource use in the economic model to reflect clinical practice. Step 2: Adjust the health outcomes with trastuzumab + chemotherapy to match clinical practice and THEN adjust the health outcomes with chemotherapy alone such that the relative efficacy remains unchanged. If transition probabilities based on median durations applied, then approach similar to calculating and applying a hazard rate ratio (HRR). If digitised Kaplan-Meier curves applied: Iteratively adjust trastuzumab + chemotherapy curve ( or ) until median PFS or overall survival = clinical practice achieved THEN Iteratively adjust chemotherapy alone curve until HRRs = RCTs.

30 Methods 30/47 Step 3: Estimate a weighted average ICER across age groups, accounting for differences in weight and thus drug costs. Step 4: Estimate a weighted average ICER across concomitant chemotherapies. Weights were based on the proportion of patients in the Herceptin Program receiving each concomitant chemotherapy, or combination thereof, prior to progression

31 Results 31/15 ICER in real-world clinical practice Treatment postprogression Price discount Taxanes only Incremental cost ($) Life years ICER based on trial evidence = $221,245 QALYs LYG ICER ($/LYG)* QALYs gained ICER ($/QALY)* No 0% No 13, , ,702 Yes 0% No 24, , ,847 No 80% No 6, , ,767 Yes 80% No 8, , ,396 No 0% Yes 12, , ,288 No 80% Yes 6, , ,009 Weighted average net gain/loss from approving trastuzumab Treatment postprogression Price discount Taxanes only Weighted average health outcomes from approving trastuzumab* Weighted average net gain/loss from approving trastuzumab* Life Years gained QALYs gained $60,000/QALY $80,000/QALY No 0% No -40,489,475-33,436,845 Yes 0% No -92,309,978-85,257, No 80% No -9,167,004-2,114,374 Yes 80% No -19,531,104-12,478,474 No 0% Yes -34,109,410-26,211, No 80% Yes -5,066,797 2,831,005 * The ICER and the net loss (gain) is likely to be slightly overestimated (underestimated) due to the inability to control for cross-over. CENTRE FOR THE HEALTH ECONOMY 31

32 Conclusions

33 Conclusions 33/47 Trastuzumab = very high cost drug with a very high ICER The ICER was a little lower or much higher, depending whether you considered treatment post-progression. Unenforced treatment guidelines can significantly reduce cost-effectiveness in clinical practice Treatment past-progression and concomitant chemotherapies CENTRE FOR THE HEALTH ECONOMY 33

34 Conclusions 34/47 In 2001 the available evidence was sufficiently certain to make a decision Sensitivity analysis and best-case scenario ICER remained above the range considered acceptable. Value of collecting observational data was low However no uncertainty around Kaplan-Meier curves or coefficients of the fitted parametric functions, and not able to adjust for cross-over. Should not have established Herceptin Program without a price discount A Coverage with Evidence Development (CED) recommendation was not appropriate on the basis of collecting observational data Another type of risk-share arrangement should have been considered CENTRE FOR THE HEALTH ECONOMY 34

35 Thank you

36 Funding and ethics approvals 36 This research forms part of the CHEETAH programme, which is funded by a NHMRC Capacity Building Grant in Health Services Research (NHMRC ID: ) The analysis of the Herceptin Program data was approved by the NSW Population & Health Services Research Ethics Committee (protocol HREC/10/CIPHS/11), the Medicare Australia External Request Evaluation Committee (2010/CO07329), and is a part of a research program approved by the University of Technology Sydney Research Ethics Committee (UTS HREC REF NO P). CENTRE FOR THE HEALTH ECONOMY

A CASE STUDY OF VALUE OF INFORMATION

A CASE STUDY OF VALUE OF INFORMATION A CASE STUDY OF VALUE OF INFORMATION, Research Fellow 1/19 Background The ISPOR good practices for performance-based risk-sharing arrangements task force recommends using value of information analysis

More information

Background 1. Comparative effectiveness of nintedanib

Background 1. Comparative effectiveness of nintedanib NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung

More information

Background Comparative effectiveness of nivolumab

Background Comparative effectiveness of nivolumab NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued

More information

Technology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta257

Technology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta257 Lapatinib or trastuzumab in combination with an aromatase inhibitor for the firstline treatment of metastatic hormone- receptor-positive e breast cancer that overexpresses HER2 Technology appraisal guidance

More information

Technology appraisal guidance Published: 23 February 2011 nice.org.uk/guidance/ta214

Technology appraisal guidance Published: 23 February 2011 nice.org.uk/guidance/ta214 Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Technology appraisal guidance Published: 23 February 2011 nice.org.uk/guidance/ta214 NICE 2018. All rights

More information

Setting The setting was secondary care. The economic study was conducted in the USA.

Setting The setting was secondary care. The economic study was conducted in the USA. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis Elkin E B, Weinstein K C, Winer E P, Kuntz K M, Schnitt S J, Weeks J C Record Status This is a critical

More information

Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.

Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a

More information

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE do not recommend reimbursement of pertuzumab.

The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE do not recommend reimbursement of pertuzumab. Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous

More information

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Summary Background 1. Comparative effectiveness of ramucirumab

Summary Background 1. Comparative effectiveness of ramucirumab Cost-effectiveness of ramucirumab (Cyramza ) for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression following previous treatment

More information

Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531

Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject

More information

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Issue date: February 2011 Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer This guidance was developed using the single technology appraisal process NICE

More information

Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma

Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following NCPE

More information

Economic Evaluation of cabazitaxel (Jevtana ) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated

Economic Evaluation of cabazitaxel (Jevtana ) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated Economic Evaluation of cabazitaxel (Jevtana ) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. March 2012

More information

YONDELIS (TRABECTEDIN) FOR THE TREATMENT OF SOFT TISSUE SARCOMA. RESPONSE TO EVIDENCE REVIEW GROUP QUERIES (15 th April 2009)

YONDELIS (TRABECTEDIN) FOR THE TREATMENT OF SOFT TISSUE SARCOMA. RESPONSE TO EVIDENCE REVIEW GROUP QUERIES (15 th April 2009) YONDELIS (TRABECTEDIN) FOR THE TREATMENT OF SOFT TISSUE SARCOMA RESPONSE TO EVIDENCE REVIEW GROUP QUERIES (15 th April 2009) 24 th APRIL 2009 Trabectedin for the treatment of advanced metastatic soft tissue

More information

Background Comparative effectiveness of ibrutinib

Background Comparative effectiveness of ibrutinib Cost effectiveness of ibrutinib (Imbruvica ) in the treatment of patients with chronic lymphocytic leukaemia who have received 1 prior therapy, or as a first-line treatment in the presence of del(17p)

More information

Technology appraisal guidance Published: 26 February 2014 nice.org.uk/guidance/ta306

Technology appraisal guidance Published: 26 February 2014 nice.org.uk/guidance/ta306 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive e non-hodgkin's B-cell lymphoma Technology appraisal guidance Published: 26 February 2014 nice.org.uk/guidance/ta306 NICE

More information

Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy

Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness

More information

4. Aflibercept showed significant improvement in overall survival (OS), the primary

4. Aflibercept showed significant improvement in overall survival (OS), the primary Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin

More information

Technology appraisal guidance Published: 22 August 2012 nice.org.uk/guidance/ta263

Technology appraisal guidance Published: 22 August 2012 nice.org.uk/guidance/ta263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer Technology appraisal guidance Published: 22 August 2012 nice.org.uk/guidance/ta263 NICE 2018. All rights

More information

Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227

Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to

More information

Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of

More information

Cost effectiveness of

Cost effectiveness of Cost effectiveness of brentuximab vedotin (Adcetris ) for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin Lymphoma who have failed at least one autologous stem cell transplant.

More information

Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476

Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476 NICE 2018. All

More information

Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA

Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting

More information

Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma

Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following

More information

Summary. Table 1 Blinatumomab administration, as per European marketing authorisation

Summary. Table 1 Blinatumomab administration, as per European marketing authorisation Cost-effectiveness of blinatumomab (Blincyto ) for the treatment of relapsed or refractory B precursor Philadelphia chromosome negative acute lymphoblastic leukaemia in adults. The NCPE assessment of blinatumomab

More information

Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer

Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer Original Manuscript Bayesian Multiparameter Evidence Synthesis to Inform Decision Making: A Case Study in Metastatic Hormone-Refractory Prostate Cancer Medical Decision Making 1 15 Ó The Author(s) 2018

More information

Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P

Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P Record Status This is a critical abstract of an economic

More information

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced

More information

Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520

Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520 NICE 2018. All rights

More information

Technology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta391

Technology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelel Technology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta391 NICE 2017. All rights reserved. Subject

More information

Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta359

Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta359 Idelalisib for treating chronic lymphocytic leukaemia Technology appraisal guidance Published: 28 October 2015 nice.org.uk/guidance/ta359 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

1. Comparative effectiveness of liraglutide

1. Comparative effectiveness of liraglutide Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding

More information

Technology appraisal guidance Published: 24 November 2010 nice.org.uk/guidance/ta208

Technology appraisal guidance Published: 24 November 2010 nice.org.uk/guidance/ta208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer Technology appraisal guidance Published: 24 November 2010 nice.org.uk/guidance/ta208 NICE 2018. All rights reserved. Subject to

More information

Cost-effectiveness of osimertinib (Tagrisso )

Cost-effectiveness of osimertinib (Tagrisso ) Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung

More information

Summary 1. Comparative effectiveness of ataluren Study 007

Summary 1. Comparative effectiveness of ataluren Study 007 Cost-effectiveness of Ataluren (Transarna TM ) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophy gene in ambulatory patients aged 5 years and older The

More information

Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239

Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239 Fulvestrant for the treatment of locally advanced or metastatic breast cancer Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta239 NICE 2018. All rights reserved. Subject

More information

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

More information

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta378

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta378 Ramucirumab for treating advanced gastric cancer or gastro oesophageal junction adenocarcinoma previously treated with chemotherapy Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta378

More information

Setting The setting was secondary care. The economic study was carried out in Canada.

Setting The setting was secondary care. The economic study was carried out in Canada. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical

More information

Abiraterone for castration-resistantation-resistant. treated with a docetaxel-containingel-containing

Abiraterone for castration-resistantation-resistant. treated with a docetaxel-containingel-containing Abiraterone for castration-resistantation-resistant metastatic prostate cancer previously treated with a docetaxel-containingel-containing regimen Technology appraisal guidance Published: 27 June 2012

More information

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Cost Effectiveness Cost Lead: David Meads 1 st meeting: 27 September

More information

Technology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta319

Technology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma Technology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta319 NICE 2018. All rights reserved. Subject

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include

More information

Technology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192

Technology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small- cell lung cancer Technology appraisal guidance Published: 28 July 2010 nice.org.uk/guidance/ta192 NICE 2018. All rights

More information

1. Comparative effectiveness of vedolizumab

1. Comparative effectiveness of vedolizumab Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were

More information

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999

More information

An Economic Framework to Inform the Scheduling of Medicines

An Economic Framework to Inform the Scheduling of Medicines An Economic Framework to Inform the Scheduling of Medicines Dr Bonny Parkinson Senior Research Fellow Centre for the Health Economy Dr Mutsa Gumbie Research Fellow Dr Henry Cutler Director Special thanks

More information

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation

More information

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 NICE 2017. All rights reserved. Subject

More information

Lead team presentation:

Lead team presentation: Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain

More information

Slides for Committee CIC redacted

Slides for Committee CIC redacted Chair s presentation Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer 3rd Appraisal Committee

More information

Addendum to Lilly submission and audit trail Workbook Alimta UK adaptation xlsm

Addendum to Lilly submission and audit trail Workbook Alimta UK adaptation xlsm Addendum to Lilly submission and audit trail Workbook Alimta UK adaptation 181112.xlsm Changes that have affected base case results or sensitivity analyses: Worksheet jmen_resource Cells F17-F21, F29-F33

More information

Setting The setting was secondary care. The economic study was carried out in Belgium.

Setting The setting was secondary care. The economic study was carried out in Belgium. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M Record

More information

Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411

Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 NICE 2017. All rights reserved.

More information

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta370

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta370 Bortezomib for previously untreated mantle cell lymphoma Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta370 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492

Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492 Atezolizumab for untreated PD- L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492

More information

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 Panobinostat for treating multiple myeloma after at least 2 previous treatments Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 NICE 2017. All rights reserved. Subject

More information

2. Cost-Effectiveness Analysis

2. Cost-Effectiveness Analysis Cost effectiveness of nab-paclitaxel (Abraxane ) + gemcitabine as a combination therapy for metastatic pancreatic cancer in Ireland, eligible for reimbursement as a hospital only product. The National

More information

What Does Breast Cancer Treatment Cost and What Is It Worth?

What Does Breast Cancer Treatment Cost and What Is It Worth? What Does Breast Cancer Treatment Cost and What Is It Worth? Elena B. Elkin, PhD Center for Health Policy and Outcomes Memorial Sloan-Kettering Cancer Center Is This Drug Worth the Cost? Ixabepilone added

More information

Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA

Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA 1 st Appraisal Committee meeting Cost Effectiveness Committee

More information

combination with everolimus with other relevant treatment options, perc considered the results of a submitted indirect treatment comparison (ITC) that included comparisons of lenvatinib in combination

More information

Health technology The study compared three strategies for diagnosing and treating obstructive sleep apnoea syndrome (OSAS).

Health technology The study compared three strategies for diagnosing and treating obstructive sleep apnoea syndrome (OSAS). Cost-effectiveness of split-night polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome Deutsch P A, Simmons M S, Wallace J M Record Status This is a critical abstract

More information

Everolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT

Everolimus for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT for the Treatment of Advanced Renal Cell Carcinoma (arcc ) - Additional Analysis Using RPSFT Thank you very much for the opportunity to submit additional analysis in relation to the above technology appraisal

More information

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,

Common disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease, Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000

More information

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine

More information

Technology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496

Technology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, e, locally advanced or metastatic breast cancer Technology appraisal guidance Published: 20 December

More information

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer ERRATUM Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer This report was commissioned by the NIHR HTA Programme as project number 08/206/02 Completed

More information

Brentuximab vedotin for treating CD30-positive Hodgkin s lymphoma [ID722] Second appraisal committee C meeting Chair s presentation 9 November 2016

Brentuximab vedotin for treating CD30-positive Hodgkin s lymphoma [ID722] Second appraisal committee C meeting Chair s presentation 9 November 2016 Brentuximab vedotin for treating CD30-positive Hodgkin s lymphoma [ID722] Second appraisal committee C meeting Chair s presentation 9 November 2016 Current management No standard of care and no NICE guidance

More information

Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500

Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500 Ceritinib for untreated ALK-positive non- small-cell lung cancer Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500 NICE 2018. All rights reserved. Subject to Notice of

More information

Summary 1. Comparative effectiveness

Summary 1. Comparative effectiveness Cost-effectiveness of Sacubitril/Valsartan (Entresto) for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction. The NCPE has issued a recommendation regarding

More information

Technology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458

Technology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane Technology appraisal guidance Published: 19 July 2017 nice.org.uk/guidance/ta458 NICE 2018. All rights

More information

Outcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of:

Outcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of: The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes Scuffham P, Carr L Record Status This is a critical abstract of

More information

Technology appraisal guidance Published: 31 January 2018 nice.org.uk/guidance/ta502

Technology appraisal guidance Published: 31 January 2018 nice.org.uk/guidance/ta502 Ibrutinib for treating relapsed or refractory mantle cell lymphoma Technology appraisal guidance Published: 31 January 2018 nice.org.uk/guidance/ta502 NICE 2018. All rights reserved. Subject to Notice

More information

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) The NCPE has issued a recommendation regarding the cost-effectiveness of tolvaptan (Jinarc

More information

Technology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357

Technology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab Technology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357 NICE 2018. All rights reserved.

More information

Technology appraisal guidance Published: 7 March 2018 nice.org.uk/guidance/ta509

Technology appraisal guidance Published: 7 March 2018 nice.org.uk/guidance/ta509 Pertuzumab with trastuzumab and docetaxel el for treating HER2-positive breast cancer Technology appraisal guidance Published: 7 March 20 nice.org.uk/guidance/ta509 NICE 20. All rights reserved. Subject

More information

Part 1 Public handouts

Part 1 Public handouts Part 1 Public handouts Chair s presentation Trastuzumab emtansine for treating HER2- positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane Rapid

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

The impact of treatment line matching on covariates balance and cost effectiveness results: A case study in oncology

The impact of treatment line matching on covariates balance and cost effectiveness results: A case study in oncology The impact of treatment line matching on covariates balance and cost effectiveness results: A case study in oncology Xavier G.L.V. Pouwels Bram L. T. Ramaekers Manuela A. Joore Department of Clinical Epidemiology

More information

Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284

Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer Technology appraisal guidance Published: 22 May 2013 nice.org.uk/guidance/ta284 NICE 2017.

More information

How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E

How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E How cost-effective is screening for abdominal aortic aneurysms? Kim L G, Thompson S G, Briggs A H, Buxton M J, Campbell H E Record Status This is a critical abstract of an economic evaluation that meets

More information

1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016

1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016 Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background

More information

Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U

Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U Faecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis Song K, Fendrick A M, Ladabaum U Record Status This is a critical abstract of an economic evaluation

More information

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472 NICE 2018. All rights reserved.

More information

Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary

Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary The Pharmacogenomics Journal (2016), 1 15 2016 Macmillan Publishers Limited All rights reserved 1470-269X/16 www.nature.com/tpj ORIGINAL ARTICLE Cost-effectiveness of using a gene expression profiling

More information

CDF Rapid Reconsideration

CDF Rapid Reconsideration CDF Rapid Reconsideration Everolimus in combination with exemestane for treating advanced HER2- negative hormone-receptor-positive breast cancer after endocrine therapy (Cancer Drugs Fund reconsideration

More information

Pharmacoeconomics of Trastuzumab (Herceptin )

Pharmacoeconomics of Trastuzumab (Herceptin ) Pharmacoeconomics of Trastuzumab (Herceptin ) Breast Cancer Press Seminar (2008.3.3) Department of Health Economics and Epidemiology Research Graduate School of Medicine, The University of Tokyo Takashi

More information

Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1

Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1 For public no AIC or CIC Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1 1st Appraisal Committee meeting Committee

More information

Technology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183

Technology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183 Topotecan for the treatment of recurrent and stage IVB cervical cancer Technology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183 NICE 2018. All rights reserved. Subject to Notice

More information

Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489

Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489 Vismodegib for treating basal cell carcinoma Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395 Ceritinib for previously treated anaplastic lymphoma kinase positive non- small-cell lung cancer Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta5 NICE 2018. All rights reserved.

More information

Her 2 Positive Metastatic Breast Cancer

Her 2 Positive Metastatic Breast Cancer Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic

More information

Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487

Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 Venetoclax for treating chronic lymphocytic leukaemia Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT large impact on cost-effectiveness. perc discussed that one of the main factors affecting the costeffectiveness estimates was the survival estimates used in the economic model. In reviewing the clinical

More information

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374 Erlotinib and gefitinib for treating non- small-cell lung cancer that has progressed after prior chemotherapy Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta374 NICE 2017.

More information

Summary 1. Comparative effectiveness of ponatinib

Summary 1. Comparative effectiveness of ponatinib Cost-effectiveness of ponatinib (Iclusig ) as indicated for adult patients with: (i) CP-, AP-, or BP- chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to

More information

Economic Evaluation of AEDs used as monotherapy in the treatment of adults with newly diagnosed focal epilepsy

Economic Evaluation of AEDs used as monotherapy in the treatment of adults with newly diagnosed focal epilepsy 0 0 APPENDIX P Cost-effectiveness analyses Five economic models were developed as part of the guideline development, one for each of the following clinical areas:. Monotherapy for adults with newly diagnosed

More information

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta381

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta381 Olaparib for maintenance treatment of relapsed, platinum-sensitive, e, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum- based chemotherapy

More information